Allocating a Scarce Vaccine Supply That Covers Only 5% of a Population

Quick Overview

An analytical decision question about allocating 5,000 vaccine doses among 100,000 people from the seat of a public health analyst. It tests setting an explicit objective, reading population and testing data without being misled by it, turning risk estimates into a defensible allocation, and planning delivery and monitoring.

Allocating a Scarce Vaccine Supply That Covers Only 5% of a Population

Company: Walmart Labs

Role: Product Manager

Category: Product / Decision Making

Difficulty: medium

Interview Round: Other

Imagine you work as an analyst in a government health department. You have 5,000 vaccine doses for a population of 100,000 people. How would you decide who receives them? ```hint Decide what the doses are for With enough supply for one person in twenty, the plan follows from the objective. Settle which outcome you most want to prevent before choosing which data to use and how to weight it. ``` ### Clarifying Questions - Which disease is this, and is the vaccine a single dose or a series? A two-dose vaccine would cover only 2,500 people. - What data do I have about the population: age groups, health conditions, occupations, care-home residence, recent testing and case counts by group? - Is more supply expected, and when? - Are there legal or political constraints on prioritizing some groups, or a requirement to split doses across regions? ### What a Strong Answer Covers - An explicit objective (for example preventing deaths and severe illness, cutting transmission or protecting health services) and why it suits such a small supply - Using population, risk and testing data to estimate the benefit of a dose in each group, with awareness of how testing data can mislead - A transparent rule that turns those estimates into doses per group, and the ethical trade-offs it makes - Delivery: reaching each group, uptake, wastage and fair access - Monitoring results and reallocating as data or supply changes ### Follow-up Questions - If you were handed weekly test counts and positive results by age group, how would you use them, and what could mislead you? - If a much larger second shipment were due within weeks, would your first allocation change? - After the doses are given, how would you judge whether the allocation worked?

Overview: An analytical decision question about allocating 5,000 vaccine doses among 100,000 people from the seat of a public health analyst. It tests setting an explicit objective, reading population and testing data without being misled by it, turning risk estimates into a defensible allocation, and planning delivery and monitoring.

Walmart Labs logo
Walmart Labs
Apr 19, 2025
mediumProduct ManagerOtherProduct / Decision Making
0
0

Imagine you work as an analyst in a government health department. You have 5,000 vaccine doses for a population of 100,000 people. How would you decide who receives them?

Clarifying Questions Guidance

  • Which disease is this, and is the vaccine a single dose or a series? A two-dose vaccine would cover only 2,500 people.
  • What data do I have about the population: age groups, health conditions, occupations, care-home residence, recent testing and case counts by group?
  • Is more supply expected, and when?
  • Are there legal or political constraints on prioritizing some groups, or a requirement to split doses across regions?

What a Strong Answer Covers Guidance

  • An explicit objective (for example preventing deaths and severe illness, cutting transmission or protecting health services) and why it suits such a small supply
  • Using population, risk and testing data to estimate the benefit of a dose in each group, with awareness of how testing data can mislead
  • A transparent rule that turns those estimates into doses per group, and the ethical trade-offs it makes
  • Delivery: reaching each group, uptake, wastage and fair access
  • Monitoring results and reallocating as data or supply changes

Follow-up Questions Guidance

  • If you were handed weekly test counts and positive results by age group, how would you use them, and what could mislead you?
  • If a much larger second shipment were due within weeks, would your first allocation change?
  • After the doses are given, how would you judge whether the allocation worked?